Phase II Trial Evaluating Addition of Fulvestrant to Erlotinib in Patients With Stage IIIB/IV NSCLC Who Are Stable on Erlotinib and Exhibit Positivity for Estrogen or Progesterone Receptor
Erlotinib is an oral drug which is able to block endothelial growth factor receptor (EGFR).
EGFR stimulates cancer cell growth. Fulvestrant (faslodex) block estrogen hormone from
gaining access to tumor and stimulating the tumor cells to grow. Both of these drugs are
already approved by FDA but have not been studied in this combination.
We will study if the combination of these drugs will delay treatment failure. Lung cancer
tumors in both males and females can be sensitive to estrogen. Only patients whose tumor
expresses the estrogen will be eligible for the trial. Estrogen sensitivity will be tested
on previously removed tumor specimens.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
14 weeks after start of fulvestrant
Lyudmila Bazhenova, M.D.
University of California, San Diego
United States: Institutional Review Board
|Moores UCSD Cancer Center||La Jolla, California 92093-0658|